SLV308 for Treatment of Patients With Early Parkinson's Disease
Early Stage Parkinson's DiseaseThis study is a multicenter, randomized, double blind, parallel group study of 6 months' treatment with SLV308 administered as a monotherapy in patients with early stage PD. An open label safety extension to this study is planned as a separate protocol for patients who are willing and eligible to participate.
Study Evaluating Sumanirole for the Treatment of the Signs and Symptoms of Early Parkinson's Disease...
Parkinson DiseaseThe primary purpose of this study is to determine whether sumanirole, at three different dose levels, is effective and safe in the treatment of the signs and symptoms of early Parkinson's disease
Long Term Safety and Efficacy of SC Apomorphine in Treatment of "Off" Episodes in Late-Stage Parkinson's...
Parkinson DiseaseThe current protocol is designed to satisfy the need for a compassionate use treatment protocol as well as for a long-term open label follow-up study.
Melperone (an Anti-Psychotic) in Patients With Psychosis Associated With Parkinson's Disease
Parkinson's DiseasePsychotic DisordersThe purpose of this study is to evaluate the safety and efficacy of three target doses of melperone compared to placebo in the treatment of psychosis associated with Parkinson's disease. Subjects will be enrolled at approximately 20 investigational sites in the United States (U.S.) and 15 Ex-US sites. The maximum study duration will be 10 weeks. Subjects will have the option of continuing in an open-label extension study.
Study of Liatermin (r-metHuGDNF) Administered by Bilateral Intraputaminal (IPu) Infusion to Subjects...
Idiopathic Parkinson's DiseaseThis randomized study was designed to evaluate the efficacy and safety of IPu-infused liatermin (15mg/putamen/day) compared with placebo in subjects with symptomatic, levodopa-response Parkinson's disease. This study consisted of a 90-day evaluation period followed by implantation of the IPu delivery system and then a 6-month double-blind treatment period.
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia...
Parkinson's DiseaseDyskinesiaThe purpose of this study is to test multiple doses of sarizotan to establish a dose with maximal safety and efficacy for treating treatment associated dyskinesia in Parkinson's disease participants.
Efficacy of Therapeutic Interventions for Orthostatic Hypotension in Parkinson's Disease and Multiple...
Parkinson's DiseaseMultiple System Atrophy1 morePatients with Parkinson's Disease or Multiple System Atrophy (MSA), and symptoms of orthostatic hypotension, are eligible for the study. Each patient will have three weeks of conservative therapy, three weeks of therapy with fludrocortisone, and three weeks of therapy with domperidone. Autonomic testing, a symptom questionnaire, bedside blood pressure testing, and Unified Parkinson Disease Rating Scale (UPDRS) will be performed after each intervention.
Aripiprazole in Patients With Psychosis Associated With Parkinson's Disease
Parkinson's DiseasePsychosesThe purpose of this clinical research study is to assess the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease.
Study of Antidepressants in Parkinson's Disease
Parkinson DiseaseDepressionThe purpose of this study is to find out if two antidepressant medications, paroxetine and venlafaxine, can help control depression in Parkinson's disease, and if these medications affect the motor symptoms of Parkinson's disease such as tremor, stiffness, slowness, and balance.
Phase I Deep Brain Stimulation (DBS) vs. Best Medical Therapy (BMT) Trial
Parkinson's DiseaseThe goals of this study are to determine if simultaneous bilateral subthalamic nucleus stimulation or simultaneous bilateral globus pallidus stimulation is more effective in reducing symptoms of Parkinson's disease, and if deep brain stimulation or best medical therapy is more effective in improving Parkinson's disease symptoms